Update on the Role of EGFR Inhibitors in Cancer Therapeutics

  • Michalis V. Karamouzis
  • Athanassios Argiris
Part of the Cancer Treatment and Research book series (CTAR, volume 135)

The epidermal growth factor receptor (EGFR) is a type I tyrosine kinase receptor that plays a central role in signal transduction pathways that regulate key cellular functions in epithelial malignancies.After ligand binding, EGFR homo- or heterodimerizes with other members of the EGFR family of receptors, such as HER-2, and activates a signaling cascade that participates in tumor proliferation, angiogenesis, survival, and invasion/metastasis (61). Multiple studies have demonstrated that EGFR is commonly overexpressed in a variety of epithelial malignancies (Table 1) and its high expression usually correlates with worse patient outcome (4, 34).


Epidermal Growth Factor Receptor Clin Oncol Metastatic Colorectal Cancer Epidermal Growth Factor Receptor Expression Epidermal Growth Factor Receptor Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abidoye OO, Cohen EE, Wong SJ, Kozloff MF, Nattam SR, Stenson KM, Blair EA, Day, Dancey JE, Vokes EE. (2006) A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24: 5568A.Google Scholar
  2. 2.
    Akita RW, Sliwkowski MX. (2003) Preclinical studies with Erlotinib (Tarceva). Semin Oncol 30(3 Suppl 7): 15–24.PubMedGoogle Scholar
  3. 3.
    Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M. (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64: 9139–9143.PubMedCrossRefGoogle Scholar
  4. 4.
    Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350–7356.Google Scholar
  5. 5.
    Arnold D, Peinert S, Voigst W, Schmoll HJ. (2006) Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 11: 602–611.PubMedCrossRefGoogle Scholar
  6. 6.
    Baselga J, Arteaga CL. (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445–2459.PubMedCrossRefGoogle Scholar
  7. 7.
    Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A. (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568–5577.PubMedCrossRefGoogle Scholar
  8. 8.
    Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F. (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23: 5323–5333.PubMedCrossRefGoogle Scholar
  9. 9.
    Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. (2006) Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12: 4671–4677.PubMedCrossRefGoogle Scholar
  10. 10.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.PubMedCrossRefGoogle Scholar
  11. 11.
    Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O’Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305–5312.Google Scholar
  12. 12.
    Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. (2005) Phase III randomized trial of ciplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646–8654.PubMedCrossRefGoogle Scholar
  13. 13.
    Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96: 1133–1141.PubMedGoogle Scholar
  14. 14.
    Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643–655.PubMedCrossRefGoogle Scholar
  15. 15.
    Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. (2006) Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17: 1120–1127.PubMedCrossRefGoogle Scholar
  16. 16.
    Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang AY. (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23: 3568–3576.PubMedCrossRefGoogle Scholar
  17. 17.
    Chan AT, Ma B, Hui EP. (2006) Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC). J Clin Oncol 24: 15509A.CrossRefGoogle Scholar
  18. 18.
    Chua DT, Nicholls JM, Sham JS, Au GK. (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59: 11–20.PubMedGoogle Scholar
  19. 19.
    Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803–1810.PubMedCrossRefGoogle Scholar
  20. 20.
    Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980–1987.PubMedCrossRefGoogle Scholar
  21. 21.
    Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. (2005) Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 8418–8424.PubMedCrossRefGoogle Scholar
  22. 22.
    Cohen EE. (2006) Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2659–2665.PubMedCrossRefGoogle Scholar
  23. 23.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.PubMedCrossRefGoogle Scholar
  24. 24.
    Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-smal-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900–5909.PubMedCrossRefGoogle Scholar
  25. 25.
    Fields ALA, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, Leopold LH, Berger MS. (2005) An open-label multicenter phase II study of oral lapatinib (GW572016) as single-agent, second-line therapy in patients with metastatic colorectal cancer. A phase II, open-label, multucenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU in combination with irinotecan and/or oxaliplatin. J Clin Oncol 23: 3583A.Google Scholar
  26. 26.
    Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237–2246.PubMedCrossRefGoogle Scholar
  27. 27.
    Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. (2005) Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 92: 1–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, Von Pawel J. (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22: 619A.Google Scholar
  29. 29.
    Geyer CE, Forster JK, Cameron D, Chan S, Pienkowski T, Romieu CG, Jagiello-Gruszweld A, Crown J, Kaufman B, Chan A. (2006) A phase III randomized, open-label, international study comparing lapatinib and capecitabine versus capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Proc Am Soc Clin Oncol 2006.Google Scholar
  30. 30.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial–INTACT 1. J Clin Oncol 22: 777–784.PubMedCrossRefGoogle Scholar
  31. 31.
    Giaccone G. (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 23: 3235–3242.PubMedCrossRefGoogle Scholar
  32. 32.
    Gibson TB, Ranganathan A, Grothey A. (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6: 29–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel W. (2006) Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94: 1293–1299.PubMedCrossRefGoogle Scholar
  34. 34.
    Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824–832.Google Scholar
  35. 35.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809–820.PubMedCrossRefGoogle Scholar
  36. 36.
    Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31–53.PubMedCrossRefGoogle Scholar
  37. 37.
    He H, Levitzki A, Zhou HJ, Walker F, Burgess A, Maruta H. (2001) Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem 276: 26741–26744.PubMedCrossRefGoogle Scholar
  38. 38.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22: 785–794.PubMedCrossRefGoogle Scholar
  39. 39.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892–5899.PubMedCrossRefGoogle Scholar
  40. 40.
    Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5578–5587.PubMedCrossRefGoogle Scholar
  41. 41.
    Hurwitz H, Febrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.PubMedCrossRefGoogle Scholar
  42. 42.
    Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T. (2006) Prospective phase II study of gefitinib for chemotherapy naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340–3346.PubMedCrossRefGoogle Scholar
  43. 43.
    Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706–3712.PubMedCrossRefGoogle Scholar
  44. 44.
    Kalyankrishna S, Grandis JR. (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666–2672.PubMedCrossRefGoogle Scholar
  45. 45.
    Kamangar F, Dores GM, Anderson WF. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137–2150.PubMedCrossRefGoogle Scholar
  46. 46.
    Kane MA, Cohen E, List M, Mehrotra B, Gustin D, Mauer A, Cella D, Vokes E. (2004) Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 22: 5586A.Google Scholar
  47. 47.
    Karamouzis MV, Gorgoulis VG, Papavassiliou AG. (2002) Transcription factors and neoplasia: vistas in novel drug design. Clin Cancer Res 8: 949–961.PubMedGoogle Scholar
  48. 48.
    Kelly H, Goldberg RM. Systemic (2005) Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence. J Clin Oncol 23:C4553–4560.CrossRefGoogle Scholar
  49. 49.
    Kelly K, Herbst RS, Crowley JJ, McCoy J, Atkins JN, Lara PN, Dakhil SR, Albain KS, Kim ES, Gandara DR. (2006) Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A Randomized Phase II study selectional trial SWOG 0342. J Clin Oncol 24: 7015A.Google Scholar
  50. 50.
    Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792.PubMedCrossRefGoogle Scholar
  51. 51.
    Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919–8923.PubMedCrossRefGoogle Scholar
  52. 52.
    Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J. (2005) Randomized phase II study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer—PARC: study protocol [ISRCTN56652283]. BMC Cancer 5: 131.PubMedCrossRefGoogle Scholar
  53. 53.
    Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in asymptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149–2158.PubMedCrossRefGoogle Scholar
  54. 54.
    Kuo T, Cho C, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. (2005) Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23: 5613–5619.PubMedCrossRefGoogle Scholar
  55. 55.
    Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, Riggins GJ. (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62: 3335–3339.PubMedGoogle Scholar
  56. 56.
    Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, Tao Q, Soong R, Goh BC. (2006) Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics 16: 73–74.PubMedCrossRefGoogle Scholar
  57. 57.
    Leong JL, Loh KS, Putti TC, Goh BC, Tan LK. (2004) Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114: 153–157.PubMedCrossRefGoogle Scholar
  58. 58.
    Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Pierre Laurent-Puig P. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992–3995.Google Scholar
  59. 59.
    Lilenbaum R, Bonomi P, Ansari R, Lynch T, Govindan R, Janne P, Hanna N. (2005) A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results. J Clin Oncol 23: 7036A.Google Scholar
  60. 60.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.PubMedCrossRefGoogle Scholar
  61. 61.
    Mendelsohn J, Baselga J. (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550–6555.PubMedCrossRefGoogle Scholar
  62. 62.
    Miller VA, Zakowski M, Riely GJ, Pao W, Ladanyi M, Tsao AS, Sandler A, Herbst R, Kris MG, Johnson DG. (2006) EGFR mutations and copy number, EGFR expression and KRAS mutation as predictors of outcome with erlotinib in bronchioalveolar cell carcinoma (BAC). Results of a prospective study. J Clin Oncol 24: 364A.CrossRefGoogle Scholar
  63. 63.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding K, Christy-Bittel J, Parulekar W. (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23: 1A.Google Scholar
  64. 64.
    Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279–286.PubMedCrossRefGoogle Scholar
  65. 65.
    Nicholson RI, Hutcheson IR, Knowlden JM. (2004) Non-endocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10: 346S–354S.PubMedCrossRefGoogle Scholar
  66. 66.
    Niederle N, Freier W, Porschen R. (2005) Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. Results of a two-cohort multicenter phase II study. Eur J Cancer 3(suppl 3): 184.Google Scholar
  67. 67.
    Oliveira S, Van Bergen en Heneqouwen PM, Storm G, Schiffelers RM. (2006) Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin Biol Ther 6: 605–617.Google Scholar
  68. 68.
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinb therapy. Science 304: 1497–1500.PubMedCrossRefGoogle Scholar
  69. 69.
    Pao W, Miller VA. (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556–2568.PubMedCrossRefGoogle Scholar
  70. 70.
    Patel JD, Pasche B, Argiris A. (2004) Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol 50: 175–186.PubMedCrossRefGoogle Scholar
  71. 71.
    Paz-Ares L, Sanchez JM, Garcia-Velasco A, Massuti B, López-Vivanco G, Provencio M, Montes A, Isla D, Amador ML, Rosell R. (2006) A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24: 7020A.CrossRefGoogle Scholar
  72. 72.
    Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. (2004) Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer. J Clin Oncol 22: 3238–3247.Google Scholar
  73. 73.
    Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ. (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072–1078.PubMedCrossRefGoogle Scholar
  74. 74.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Süto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci S, Gelber RD. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672.PubMedCrossRefGoogle Scholar
  75. 75.
    Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi J, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N. (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II Randomised Trial. Lancet Oncol 6: 383–391.PubMedCrossRefGoogle Scholar
  76. 76.
    Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. (2005) Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23: 9089–9096.PubMedCrossRefGoogle Scholar
  77. 77.
    Romond EH, Perez SA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.PubMedCrossRefGoogle Scholar
  78. 78.
    Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U. (2004) Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 22: 7012A.Google Scholar
  79. 79.
    Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ. (2005) Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23: 9265–9274.PubMedCrossRefGoogle Scholar
  80. 80.
    Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. J Clin Oncol 21: 817A.CrossRefGoogle Scholar
  81. 81.
    Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopitz J, Mayer RJ. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208.PubMedCrossRefGoogle Scholar
  82. 82.
    Saltz LB, Lenz H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Wetherbee S, Chen H. (2005) Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan-Refractory Colorectal Cancer. J Clin Oncol 23: 3508A.Google Scholar
  83. 83.
    Savvides P, Argarwala SS, Greskovich J, Argiris A, Bokar J, Cooney M, Hoppel C, Stepnick DW, Lavertu P, Remick S. (2006) Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 24: 5545A.CrossRefGoogle Scholar
  84. 84.
    Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331S–336S.PubMedCrossRefGoogle Scholar
  85. 85.
    Schlessinger J. (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669–672.PubMedCrossRefGoogle Scholar
  86. 86.
    Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ, Ellis LM. (2001) Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85: 584–589.PubMedCrossRefGoogle Scholar
  87. 87.
    Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.PubMedCrossRefGoogle Scholar
  88. 88.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.PubMedCrossRefGoogle Scholar
  89. 89.
    Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77–85.PubMedCrossRefGoogle Scholar
  90. 90.
    Spector NL, Blackwell K, Hurley J, Harris JL, Lombardi D, Bacus S, Ahmed SB, Boussen H, Frikha M, Ayed FB. (2006) EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. J Clin Oncol 24: 502A.Google Scholar
  91. 91.
    Stevenson D, Charalambous C, Wilson JB. (2005) Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperplasia, with subsequent up-regulation of p16 and MMP9. Cancer Res 65: 8826–8835.PubMedCrossRefGoogle Scholar
  92. 92.
    Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM. (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22: 3080–3090.PubMedCrossRefGoogle Scholar
  93. 93.
    Tao Y, Song X, Deng X, Xie D, Lee LM, Liu Y, Li W, Li L, Deng L, Wu Q, Gong J, Cao Y. (2005) Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res 303: 240–251.PubMedCrossRefGoogle Scholar
  94. 94.
    Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan E, Pemberton K, Archer V. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537.PubMedCrossRefGoogle Scholar
  95. 95.
    Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. (2005) Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23: 8786–8793.PubMedCrossRefGoogle Scholar
  96. 96.
    Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR. (2003) Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 63: 5629–5635.PubMedGoogle Scholar
  97. 97.
    Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF, Shimizu N. (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66: 1371–1375.PubMedCrossRefGoogle Scholar
  98. 98.
    Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Bessa EH, Baselga J, Vermorken JB. (2004) Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. J Clin Oncol 22: 488A.Google Scholar
  99. 99.
    Tsao M, Zhu C, Sakurada A, Zhang T, Whitehead M, Kamel-Reid S, Ding K, Seymour L, Shepherd F. (2006) An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 24: 365A.Google Scholar
  100. 100.
    Tyagi P. (2005) Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 5: 21–23.PubMedGoogle Scholar
  101. 101.
    Yarden Y, Sliwkowski MX. (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.PubMedCrossRefGoogle Scholar
  102. 102.
    Yu H, Jove R. (2004) The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 4:97–105.PubMedCrossRefGoogle Scholar
  103. 103.
    Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23: 3536–3544.PubMedCrossRefGoogle Scholar
  104. 104.
    Venook A, Niedzwieski D, Hollis D, Sutherland S, Goldberg R, Alberts S, Benson A, Wade J, Schilsky R, Mayer R. (2006) Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results. J Clin Oncol 24: 3509A.CrossRefGoogle Scholar
  105. 105.
    Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J, Dekker A. (2005) A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 23: 5504A.CrossRefGoogle Scholar
  106. 106.
    von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Lück HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A. (2005) A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165–172.CrossRefGoogle Scholar
  107. 107.
    von Pawel J, Park K, Pereira R, Szczesna A, Yu C, Ganul VL, Krzakowski M, Roh JK, Pilz K, Pirker R. (2006) Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first line treatment for patients with epidermal growth factor (EGFR)–expressing advanced non-small cell lung cancer (NSCLC) (FLEX). J Clin Oncol 24: 7109A.Google Scholar
  108. 108.
    Xu JM, Paradiso A, McLeod HK. (2004) Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design? Eur J Cancer 40: 1807–1809.PubMedCrossRefGoogle Scholar
  109. 109.
    Wainberg Z, Hecht JR. (2006) A Phase III Randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 5: 363–367.PubMedCrossRefGoogle Scholar
  110. 110.
    Willmore-Payne C, Holden JA, Layfield LJ. (2006) Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 19: 634–640.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Michalis V. Karamouzis
    • 1
  • Athanassios Argiris
    • 1
  1. 1.Division of Hematology-Oncology, Department of MedicineUniversity of PittsburghPennsylvaniaUSA

Personalised recommendations